NUT family member 2BGenealiases: FAM22B · bA119F19.1
Q-omics provides the consensus-scored NUTM2B profile across patient tissues and cancer cell-line models. NUTM2B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NUTM2B is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, NUTM2B RNA expression shows 16,548 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, KICH, and TGCT as cancer lineages where NUTM2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTM2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTM2B survival associations across molecular data types. NUTM2B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTM2B RNA expression–survival associations across cancer types. High NUTM2B expression shows unfavorable associations in ACC and ESCA, but favorable associations in UCS, BRCA, LGG and CESC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for NUTM2B RNA expression.
This table summarizes NUTM2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for NUTM2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTM2B shows lower tumor expression in KICH, LUAD, COAD, KIRC and THCA and higher tumor expression in CHOL. The KICH box plot shows higher NUTM2B RNA expression in normal versus tumor tissue (log2 FC = −0.354, t-test p < 0.001).
This table shows molecular features associated with NUTM2B in patient tissues and cancer cell lines. In patient samples, NUTM2B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NUTM2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
